📊 BMEA Key Takeaways
Investment Thesis
Biomea Fusion is a pre-revenue stage pharmaceutical company burning significant cash with minimal revenue generation and substantial operating losses. The company faces critical runway constraints despite maintaining a strong cash position, with operating cash burn of -$56.4M annually against only $46.6M in cash reserves.
BMEA Strengths
- Strong liquidity position with $46.6M in cash and 3.18x current ratio
- No long-term debt burden providing financial flexibility
- Early-stage biotech model with R&D focus appropriate for drug development
BMEA Risks
- Severe operating losses of -$71.8M with only $5.4M revenue indicates minimal commercial traction
- Negative free cash flow of -$56.4M annually creates urgent funding need within 12 months
- Extreme negative margins (-1233.5% net margin) indicate business model is not yet viable
- No insider purchases in 90 days suggests lack of management confidence
- High cash burn relative to remaining runway creates existential dilution risk
Key Metrics to Watch
- Revenue growth trajectory and clinical trial progress
- Monthly cash burn rate and projected runway
- Cash position relative to operating expenses
- Pipeline advancement and regulatory milestones
- Future financing needs and dilution impact
BMEA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.18x current ratio provides a solid financial cushion.
BMEA Profitability Ratios
BMEA vs Healthcare Sector
How Biomea Fusion, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BMEA Balance Sheet & Liquidity
BMEA 5-Year Financial Trend
5-Year Trend Summary: Biomea Fusion, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.80 indicates the company is currently unprofitable.
BMEA Growth Metrics (YoY)
BMEA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | $1.2B | -$5.9M | $-0.43 |
| Q2 2022 | $1.1B | -$5.9M | N/A |
| Q1 2022 | $1.1B | -$5.9M | N/A |
| Q3 2021 | $1.1B | -$293.0K | N/A |
| Q2 2021 | $1.1B | -$293.0K | N/A |
| Q1 2021 | $1.1B | -$398.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BMEA Capital Allocation
BMEA SEC Filings
Access official SEC EDGAR filings for Biomea Fusion, Inc. (CIK: 0001840439)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BMEA
What is the AI rating for BMEA?
Biomea Fusion, Inc. (BMEA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMEA's key strengths?
Strong liquidity position with $46.6M in cash and 3.18x current ratio. No long-term debt burden providing financial flexibility.
What are the risks of investing in BMEA?
Severe operating losses of -$71.8M with only $5.4M revenue indicates minimal commercial traction. Negative free cash flow of -$56.4M annually creates urgent funding need within 12 months.
What is BMEA's revenue and growth?
Biomea Fusion, Inc. reported revenue of $5.4M.
Does BMEA pay dividends?
Biomea Fusion, Inc. does not currently pay dividends.
Where can I find BMEA SEC filings?
Official SEC filings for Biomea Fusion, Inc. (CIK: 0001840439) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMEA's EPS?
Biomea Fusion, Inc. has a diluted EPS of $-1.45.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.